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The article by Lall et al.1 published in Clinical and Molecular 
Hepatology  fuels the discussion on differentiating laboratory 
markers between acute hepatitis B (AHB) and acute exacerbation 
of chronic hepatitis B (CHB-AE). This small retrospective study, 
which included 172 patients with AHB (n=89) or CHB-AE (n=83), 
had numerous strengths such as relevantly good follow-up, base-
line assessment of IgM anti-HBc level, prothrombin time (PT), HBV 
DNA level, as well as qHBsAg and HBeAg values. The median cut-
off ratio of IgM anti-HBc was significantly higher in AHB (30.44) 
than in CHB-AE (8.63) (P<0.01). The mean PT international nor-
malized ratio (INR) was signif icantly greater in CHB-AE 
(1.88±1.24) compared to AHB (1.62±0.17). However, such find-
ings were not new, and they must be taken with caution for sev-
eral reasons.
In clinical practice, the similarities between AHB and CHB-AE in 
both clinical and laboratory context make it difficult to distinguish 
between the two clinical entities.2 Nevertheless, differentiating 
between the two entities is important, as they have different 
prognoses and therapeutic strategies.3,4 Most patients with AHB 
recover spontaneously, and treatment may be required only in a 
small number of patients who progress to fulminant hepatitis. On 
the other hand, patients with CHB-AE generally need antiviral 
therapy, since hepatic decompensation may be developed in pa-
tients with cirrhosis, especially.5,6 According to this study, a value 
of 20.5 for signal cut-off of IgM anti-HBc and 1.27 INR can be 
used to differentiate between AHB and CHB-AE. The evaluation 
of IgM anti-HBc levels seems to be an interesting strategy for dif-
ferentiating the two clinical entities. Likewise, some reports have 
proposed that IgM anti-HBc levels should be reconsidered to de-
fine AHB.7,8 However, the diversity of reference values suggested 
from various studies is remarkable. These findings make it difficult 
to establish a standard reference value as the cut-off level.8-12 Un-
fortunately, as the author mentioned, IgM anti-HBc test was not a 
quantitative assay but a semiquantitative assay in this study. 
Therefore, the lack of prospective study about the standardization 
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of quantitative assays and any valid clinical threshold would make 
the use of this marker quite unreliable.13 Moreover, the presence 
of IgM anti-HBc, which is associated with AHB, is necessary but 
not sufficient to diagnose AHB. IgM anti-HBc can be detected 
during episodes of CHB-AE. It may be the result of inflammation 
and liver cell injury during flare-ups of hepatitis, with consequent 
release of high concentrations of the nucleocapsid protein. These 
proteins lead to the activation of pre-existing plasma cells which 
are released into the circulation, and eventually contribute to the 
secretion of IgM anti-HBc during acute exacerbation.14 It can also 
lead to a misdiagnosis of AHB.
In addition, PT is not effective in differentiating between two 
entities, due to its short half-life and data obtained only at a one-
time point. In particular, the proportion of cirrhosis was more than 
70% in CHB-AE. PT is affected by the presence of cirrhosis. There-
fore, PT seems to have poor sensitivity and specificity to discrimi-
nate between two entities.
Among other diagnosis tools, the avidity index of IgG anti-HBc 
is defined as the strength of IgG binding to antigenic epitopes of 
hepatitis B virus (HBV).15 This increases as IgG matures. Therefore, 
the low avidity index of IgG anti-HBc is an indicator of AHB, and 
high avidity index refers to CHB-AE. Terkmani et al.16 reported 
that an avidity index ≤3.4 was highly predictive of AHB. A quan-
titative and kinetics analysis of HBsAg titer is also worth applying. 
In AHB, HBsAg titer disappears much faster.17,18 Various possible 
serological studies have been performed. A combination study of 
HBV DNA, HBsAg, and IgM anit-HBc quantification sought to find 
the best strategy to discriminate between AHB and CHB-AE. Most 
of the results showed that AHB tends to show high IgM anti-HBc 
and low serum HBV DNA and HBsAg titer compared to CHB-AE.19 
These findings originate from a vigorous immune response in 
acute viral infection.
So, do we need to go out of the way to differentiate between 
AHB and CHB-AE in the era of high potent antiviral agents? The 
KASL clinical practice guidelines for the management of CHB pro-
posed that nucleoside analogues can be initiated in patients with 
severe AHB (e.g., coagulopathy, severe jaundice, liver failure).6 
Other patients with AHB can be free of the virus without antiviral 
therapy, and do not progress to chronic illness. In addition, Brah-
mania et al.20 reported that alanine aminotransferase (ALT) flares 
rarely lead to significant decompensation in CHB patients with 
minimal fibrosis. In this case, it might be prudent to monitor the 
patients, rather than treating them.
Likewise, in patients with HBeAg-positive or HBeAg-negative 
CHB, prompt antiviral therapy should be initiated in the case of 
acute exacerbation, with the elevation of ALT ≥5–10 times the 
upper limit of normal, and signs of liver failure such as jaundice, 
PT prolongation, ascites, or hepatic encephalopathy.6 Therefore, 
the indication of antiviral therapy is similar between the two enti-
ties. There is no urgent need to establish the criteria and addi-
tional strategies for correct classification of AHB or CHB-AE in the 
era of highly potent and safe antiviral agents.
However, although the amount of clinical interest is low, it 
would help the physician to understand the natural course of HBV 
to find the gold standard for better defining and differentiating 
AHB from CHB-AE. Hopefully, the combination of new biomark-
ers, such as hepatitis B core-related antigen, HBV RNA, and im-
munologic markers (cytokine, chemokine profiles), will lead to dif-
ferential diagnosis between AHB and CHB-AE.
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